Compare FPI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | PHAR |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.2M | 1.1B |
| IPO Year | 2014 | N/A |
| Metric | FPI | PHAR |
|---|---|---|
| Price | $9.82 | $17.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 633.0K | 23.0K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 296.76 | N/A |
| EPS | ★ 1.27 | 0.00 |
| Revenue | $52,990,000.00 | ★ $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ $7.82 | $3,089.47 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $9.37 | $7.50 |
| 52 Week High | $12.87 | $18.12 |
| Indicator | FPI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 54.31 |
| Support Level | $9.65 | $16.15 |
| Resistance Level | $10.53 | $17.00 |
| Average True Range (ATR) | 0.15 | 0.76 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 11.88 | 53.81 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.